Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol.

Title: The Lancet. Oncology

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): Jun 2015

Volume: 16

Issue: 6

Affiliations

[1 ] Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jychang@mdanderson.org.

[2 ] Department of Radiation Oncology, VU University Medical Center, Amsterdam, Netherlands.

[3 ] Department of Cardiothoracic Surgery, VU University Medical Center, Amsterdam, Netherlands.

[4 ] Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[5 ] Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[6 ] Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.

[7 ] Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[8 ] Department of Radiation Oncology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands.

[9 ] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[10 ] Department of Pulmonary Diseases, Catharina Hospital, Eindhoven, Netherlands.

[11 ] Department of Radiation Oncology, Catharina Hospital, Eindhoven, Netherlands.

[12 ] Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.

[13 ] Phoenix CyberKnife and Radiation Oncology Center, Phoenix, AZ, USA.

[14 ] Department of Pulmonary Diseases, Maastricht University Medical Center, Netherlands.

[15 ] Kona Medical, Bellevue, WA, USA.

[16 ] Department of Radiation Oncology, CHI St Luke's Health, Houston, TX, USA.

[17 ] Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[18 ] Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, Netherlands.

Article

Publisher Item ID: S1470-2045(15)70168-3 Mid ID: NIHMS695867

DOI: 10.1016/S1470-2045(15)70168-3

PubMed ID: 25981812

SO-VID: 8eb2e1a6-6c08-4a08-9fa1-cfefcde79efb

History

Data availability:

Comments

Comment on this article

scite_

Cited by 380

See all cited by

- Version 1
- Version 1